# US 9,040,557 B2 · Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,557 B2
- Document ID: US9040557B2
- Status: Granted
- Kind: B2
- Application number: 13/578,717
- Filed: 2010-12-14
- Published: 2012-12-20
- Granted: 2015-05-26
- Earliest claimed: 2010-01-19
- Assignees: Yonsei University Technology Holdings, Inc.
- Applicants: Tae Sun Park
- Inventors: Tae Sun Park
- Web page: https://patentgrep.com/patent/US9040557B2

## CPC

- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/49: Cinchonan derivatives, e.g. quinine
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 5/48: of the pancreatic hormones
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising cinchonine as an active ingredient. The composition of the present invention comprising cinchonine as an active ingredient contributes to not only inhibition of adipocyte differentiation but also reductions of body weight, visceral fat, total cholesterol level, plasma triglyceride level and liver tissue triglyceride level, thereby exerting prevention or treatment efficacies of obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases.

## Claims

### Claim 1

A method for decreasing lipid levels, treating obesity, or treating fatty liver in a subject in need thereof, the method comprising administering to the subject a composition comprising cinchonine as an active ingredient.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the composition reduces differentiation of adipocytes.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the composition decreases blood fat, liver fat or visceral fat.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the fat comprises triglyceride, cholesterol or free fatty acids.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the visceral fat is one or more selected from the group consisting of epididymal fat, perirenal fat, mesenteric fat and retroperitoneal fat.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the composition decreases the level of ALT (alanine aminotransferase) or AST (aspartate aminotransferase).

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition decreases the expression of PPARγ (Peroxisome proliferator activated receptor gamma), C/EBPs (CCAAT enhancer-binding proteins) or aP2 (fatty acid binding protein).

### Claim 8 (depends on 1)

The method according to claim 1, wherein the composition decreases the expression of TNF-α (tumor necrosis factor-alpha) and IL-6 (interleukin-6).

### Claim 9 (depends on 1)

The method according to claim 1, wherein the composition increases the expression of UCP2 (uncoupling protein 2) or UCP3 (uncoupling protein 3).

### Claim 10 (depends on 1)

The method according to claim 1, wherein the composition decreases the glucose level in blood.

### Claim 11 (depends on 1)

The method according to claim 1, wherein cinchonine is derived from plants.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the composition is a pharmaceutical composition.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the composition is a food composition.